{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '10. Subject is currently taking concomitant immunosuppressive drugs, including systemic', 'corticosteroids, within 2 weeks of Visit 2 (Baseline).', '11. Subject has untreated secondary infections; however, subject may become eligible after', \"successful treatment of his/her infection(s) at the Investigator's discretion.\", '12. Subject is currently enrolled in an investigational drug or device study or has used an', 'investigational drug or investigational device treatment within 30 days prior to Visit 2', '(Baseline).', '13. Subject has lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated', 'skin cancers within the Treatment/Assessment Areas.', \"14. Subject has a physical condition or other dermatologic disorder that, in the Investigator's\", 'opinion, might impair evaluation of CI, or that exposes the subject to unacceptable risk by', 'study participation.', '15. Subjects with ALT or AST > 2 X Upper Limit of Normal (ULN) and creatinine > 1.5 X ULN.', '16. Subject is unable to communicate or cooperate with the Investigator due to language problems,', 'impaired cerebral function, or physical limitations.', '17. Subject has a history of drug or alcohol abuse within the past 6 months, or if suspected to be', 'noncompliant or is unlikely to comply with the requirements of the study protocol (eg, due to', 'alcoholism, drug dependency, mental incapacity) in the opinion of the Investigator.', '18. Subject has a history of sensitivity to any of the ingredients in the study treatments (see', 'Section 6.1).', '5.3', 'Lifestyle Considerations', '5.3.1', 'Meals and Dietary Restrictions', 'Subjects must fast at least 8 hours prior to the collection of specimens for clinical laboratory testing', 'at Visit 1 (Screening) and, if possible, for Visit 6 (EOS). However, if a subject arrives at the clinic', 'for Visit 6 (EOS) without having fasted for at least 8 hours, laboratory specimens may be collected', 'as non-fasting, at the discretion of the Investigator and documented as such on the laboratory', 'requisition form.', '5.3.2', 'Activity', 'No activity restrictions are applicable.', '5.4', 'Screen Failures', 'Screen failures are defined as subjects who consent to participate in the clinical study but are not', 'subsequently randomized into the study. A minimal set of screen failure information is required to', 'ensure transparent reporting of screen failure subjects to meet the Consolidated Standards of', 'Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory', 'authorities. Minimal information includes demography, eligibility criteria, and any serious adverse', 'event (SAE) will be collected and recorded in the electronic data capture system.', '26']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Individuals who do not meet the criteria for participation in this study (screen failure) may be', 'rescreened.', 'Eligible subjects who are not able to complete all their screening assessments within the designated', 'screening period may be rescreened at the discretion of the Sponsor. Rescreening for other reasons', 'may be allowed after consultation with the Sponsor. All screening assessments except for the', 'ICF/Assent, confirmation of CI diagnosis, height, and buccal swab for DNA will be repeated', 'unless determined otherwise by the Sponsor.', 'Participants who have a clinically nonsignificant out-of-range laboratory result may be rescreened', '1 time only at the discretion of the Investigator and after consultation with the Sponsor. For normal', 'ranges, refer to the Laboratory Manual.', 'Rescreened subjects should not be assigned the same subject number as for the initial screening.', '27']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '6.0 STUDY TREATMENT', '6.1', 'Study Treatment(s) Administered', 'The blinded study treatments to be used in this study include:', 'TMB-001, 0.05%, bid', 'TMB-001, 0.1%, bid', 'Vehicle Ointment (Control) bid', 'The study medication is intended to be applied twice daily, ideally once in the morning and once', 'in the evening, but at least 6 hours apart.', 'Subjects are instructed to use the indicated amount of study medication on the VIIS', 'Treatment/Assessment Areas. Refer to the Subject and Site Instruction Sheet for per protocol', \"amounts of medication to be applied based on subject's BSA%.\", 'Product application will be clearly demonstrated by the Investigator or a designated healthcare', 'professional at the Baseline Visit.', 'The study treatment details are provided in Table 2. The Vehicle ointment contains only the', 'inactive ingredients and color additive so that the active and vehicle formulations are', 'indistinguishable.', 'The Treatment/Assessment Areas are described in Section 4.1.2.', 'Table 2', 'Study Treatments', 'Study Treatment Name:', 'TMB-001 0.05%', 'TMB-001 0.1%', 'Vehicle', 'Dosage Formulation:', 'Ointment', 'Ointment', 'Ointment', 'Unit Dose', 'Strength(s)/Dosage', '0.05%', '0.1%', 'Not applicable', 'Level(s):', 'Route of Administration', 'Topical', 'Topical', 'Topical', 'Dosing Instructions:', 'Twice daily (morning', 'Twice daily (morning', 'Twice daily (morning and', 'and evening)', 'and evening)', 'evening)', 'Study medication will', 'Study medication will', 'be provided in', 'Vehicle ointment will be', 'aluminum tubes.', 'be provided in', 'provided in aluminum tubes.', 'aluminum tubes. Each', 'Packaging and Labeling', 'Each aluminum tube', 'Each aluminum tube will be', 'aluminum tube will be', 'will be labeled as', 'labeled as required per', 'labeled as required per', 'required per country', 'country requirement.', 'country requirement.', 'requirement.', 'Ferndale Laboratories', 'Ferndale Laboratories', 'Ferndale Laboratories in', 'Manufacturer', 'in Ferndale,', 'in Ferndale, Michigan,', 'Ferndale, Michigan, USA', 'Michigan, USA', 'USA', '28']\n\n###\n\n", "completion": "END"}